Fabrication and characterization of a rapid prototyped tissue engineering scaffold with embedded multicomponent matrix for controlled drug release by Chen, Muwan et al.
© 2012 Chen et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 4285–4297
International Journal of Nanomedicine
Fabrication and characterization of a rapid 
prototyped tissue engineering scaffold with 
embedded multicomponent matrix for controlled 
drug release
Muwan Chen1,2
Dang QS Le1,2
San Hein2
Pengcheng Li1
Jens V Nygaard2
Moustapha Kassem3
Jørgen Kjems2
Flemming Besenbacher2
Cody Bünger1
1Orthopaedic Research Lab, Aarhus 
University Hospital, Aarhus C,  
Denmark; 2Interdisciplinary 
Nanoscience Center (iNANO), 
Aarhus University, Aarhus C, 
Denmark; 3Department of 
Endocrinology and Metabolism, 
Odense University Hospital,  
Odense C, Denmark
Correspondence: Muwan Chen 
Orthopaedic Research Lab, Aarhus 
University Hospital, 8000 Aarhus C, 
Denmark 
Tel +45 7846 4162 
Fax +45 7846 4150 
Email chen.muwan@ki.au.dk 
 
San Hein 
Interdisciplinary Nanoscience Center 
(iNANO), Aarhus University,  
8000 Aarhus C, Denmark 
Email sanhein@inano.au.dk
Abstract: Bone tissue engineering implants with sustained local drug delivery provide an 
opportunity for better postoperative care for bone tumor patients because these implants offer 
sustained drug release at the tumor site and reduce systemic side effects. A rapid prototyped 
macroporous polycaprolactone scaffold was embedded with a porous matrix composed of 
chitosan, nanoclay, and β-tricalcium phosphate by freeze-drying. This composite scaffold 
was evaluated on its ability to deliver an anthracycline antibiotic and to promote formation 
of mineralized matrix in vitro. Scanning electronic microscopy, confocal imaging, and DNA 
quantification confirmed that immortalized human bone marrow-derived mesenchymal stem 
cells (hMSC-TERT) cultured in the scaffold showed high cell viability and growth, and good 
cell infiltration to the pores of the scaffold. Alkaline phosphatase activity and osteocalcin stain-
ing showed that the scaffold was osteoinductive. The drug-release kinetics was investigated by 
loading doxorubicin into the scaffold. The scaffolds comprising nanoclay released up to 45% of 
the drug for up to 2 months, while the scaffold without nanoclay released 95% of the drug within 
4 days. Therefore, this scaffold can fulfill the requirements for both bone tissue engineering and 
local sustained release of an anticancer drug in vitro. These results suggest that the scaffold can 
be used clinically in reconstructive surgery after bone tumor resection. Moreover, by changing 
the composition and amount of individual components, the scaffold can find application in other 
tissue engineering areas that need local sustained release of drug.
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Introduction
Repair of bone defects caused either by traumatic accidents or tumor resection poses 
major health care challenges to biomedical science and technology.1–3 Bone tissue 
engineering scaffolds have advanced greatly over the last decade and show very 
promising potential as bone graft substitutes.4,5 Scaffolds are generally composed 
of polymers and other materials which have been used in drug delivery systems for 
decades. The combined efforts of medical practitioners and material scientists enable 
fabrication of scaffolds with additional drug delivery features to which clinically 
important functionalities are added. To facilitate bone tissue formation, bioactive 
molecules like growth factors are incorporated into the scaffold.6,7 To prevent bacterial 
infection and biofilm, scaffolds have been designed to release antibiotics.8 To prevent 
cancer recurrence, chemotherapeutic drugs have been incorporated into the scaffold.9,10 
There is an increasing interest in fabrication of drug-eluting bone tissue engineering 
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scaffolds because these scaffolds provide an approach that 
conventional medical practice does not offer.11–13
One such drug-eluting scaffold is a ceramic scaffold 
which is osteoconductive and able to carry drugs. However, 
it is difficult to tune drug release profiles into desired levels.14 
Biodegradable polymeric materials such as polycaprolactone 
(PCL)15 and poly (lactic-co-glycolic acid) (PLGA)16 have 
been investigated for bone tissue engineering and local 
drug delivery. There are several techniques in fabrication 
PCL scaffolds such as freeze drying, salt leaching and rapid 
prototyping. Among them, rapid prototyping or 3D printing 
are popular because it is possible to control the pore sizes 
and shapes of the scaffold to different degrees of strength and 
biodegradability.17 However, the exclusive use of PCL and 
PLGA scaffolds has shown limited success because of their 
hydrophobicity, difficulty to control drug release, and inferior 
osteoconductivity. Thus, an optimal combination of bioma-
terials is essential in the fabrication of tunable drug-eluting 
bone scaffolds with proper mechanical strength.
Nanoclay (sodium montmorillonite) are layered silicates, 
cationic exchangers, and possess negatively charged sur-
faces with specific surface areas up to 750 m2/g.18 Cationic 
drug or polymer molecules can intercalate and exfoliate the 
clay particles to provide a stable aqueous suspension and 
improve aqueous solubility of drugs. The cation exchange 
capacity of the clay, the charge of the drug, and pH of the 
medium determine the drug-release kinetics. Additional 
clay-drug interaction mechanisms, including hydrophobic, 
hydrogen bonding, ligand exchange, and water bridging may 
also be present. These properties have encouraged the use 
of clays for controlled release of drugs.19,20 Chitosan/clay 
nanocomposites are also potential sustained drug-release 
carriers.21–23
Both chitosan and calcium phosphate compounds, eg, 
hydroxyapatite or β-tricalcium phosphate, are widely used in 
bone tissue engineering because of their osteogenic  properties. 
In addition, studies have shown that incorporation of clay with 
chitosan and hydroxyapaptite improves both mechanical and 
osteogenic scaffold properties.24,25 However, the strength of 
the composite scaffold made from the combination of clay, 
β-tricalcium phosphate, and chitosan is insufficient to implant 
in defects of a high-loading tissue such as bone.
Therefore, the mechanically stable and biodegradable 
rapid prototyped macroporous PCL scaffold was used to 
host an osteoconductive and drug-eluting porous matrix. 
The chitosan/β-tricalcium phosphate (β-TCP) composite was 
embedded into the host scaffold to improve osteoconductiv-
ity of the scaffold. The drug-loaded sodium montmorillonite 
clay was further incorporated to the chitosan/β-TCP matrix, 
providing a tunable drug-release system to the scaffold.
We used doxorubicin as a model drug because it is a 
widely used anthracycline antibiotic with a broad-spectrum 
antitumor activity to treat several types of malignancies,26–28 
especially for soft tissue and bone sarcoma.29 However, due to 
its cumulative-dose limit and myocardial toxicity, treatment 
with doxorubicin is limited.30,31 Therefore, a sustained local 
drug delivery system could overcome these drawbacks.
We have designed and tested a biocompatible, biodegrad-
able, and bioresorbable scaffold, capable of sustained drug 
release for a therapeutic strategy. The drug-loaded chitosan/
nanoclay/β-TCP composite is housed in a rapid prototyped 
polycaprolactone scaffold for this purpose. We evaluated 
this composite scaffold in vitro in terms of its bone graft 
substitute potential with hMSC and its capacity for sustained 
release of doxorubicin.
Materials and methods
The nanoclay was Cloisite Na+, Lot: 07F28GDX-008  (Southern 
Clay Products, Inc, Moosburg, Germany). The chitosan was 
Chitopharm M with 75%–85% degree of deacetylation 
( Cognis, Florham Park, NJ).  Polycaprolactone (MW = 50 kDa) 
was from Perstorp (Cheshire, UK). The β-TCP nanocrystals 
were Lot: TCPCH01 (Berkeley Advanced  Biomaterials, Inc, 
Berkeley, CA). Doxorubicin hydrochloride (DOX) was from 
Sigma-Aldrich (St Louis, MO).
Scaffold fabrication
PCL-base scaffold manufacture
Scaffolds were made from PCL by means of fused  deposition 
modeling with a BioScaffolder (SYS+ENG GmbH, 
 Ilmenau, Germany). Using a biopsy punch (Acuderm, Fort 
Lauderdale, FL), cylindrical scaffolds with a diameter of 
10 mm were punched out from 5 mm-thick porous PCL mats. 
To increase surface hydrophilicity and thus improve cell attach-
ment, the scaffolds were etched in 5 mol/L sodium hydroxide 
for 3 hours, and then in 70% ethanol for sterilization. The scaf-
folds were rinsed in sterile water multiple times and dried.
Clay modification
Our pilot study showed that the clay-DOX carrier released 
less than 10% in 1 month. Thus we modified the clay with 
chitosan as described by Yuan et al23 and in the remainder of 
this paper, “clay” denotes this modified clay.
Clay was added into 0.2% (w/v) chitosan solution prepared 
in 1.0% (v/v) acetic acid. The weight ratio of chitosan to clay 
was 10:1. After stirring for 4 hours at ∼500 rpm, the colloidal 
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suspension was centrifuged and washed three times with 1.0% 
(v/v) acetic acid in order to remove free chitosan. Finally, after 
dispersing the modified clay nanoparticles pellet in 1.0% (v/v) 
acetic acid, it was ready for scaffold fabrication.
Clay/DOX carrier
The modified clay was dispersed in DOX solution for 
12 hours and in vortex for 2 hours. Then the solution was 
centrifuged at 15,000 g for 10 minutes and the supernatant 
was collected. DOX was encapsulated into the clay nano-
particles and designated as clay/DOX carrier.
Preparation of composite scaffolds
β-TCP nanoparticles were dispersed in 1% (w/v) chitosan 
solution prepared in 1% (v/v) acetic acid. The weight ratio 
of β-TCP to chitosan was 1:20. The chitosan/β-TCP solution 
was stirred at room temperature and then divided into four 
groups: A, B, C, and D, our testing groups for drug delivery 
(Figure 1).
Modified clay was added to Group A solution and used 
as a blank scaffold for the bone tissue engineering. DOX 
was added to Group B solution and used as a control group 
for the drug delivery. Both modified clay and DOX were 
added to Group C solution. The clay/DOX carrier was 
added to Group D solution. Each PCL scaffold (thickness 
5 mm and diameter 10 mm) was immersed in 500 µL of 
each solution and was frozen at −20°C for 24 hours. Sub-
sequently, lyophilization was done at −20°C at 40 mTorr for 
48 hours with a Dura-Stop/Dura-Dry freeze dryer system 
(FTS Systems; SP Scientific, Warminster, PA). Next, the 
scaffolds were neutralized in 0.4 M NaOH in 70% ethanol 
solution for 15 minutes initially and then in 70% ethanol 
for 3 hours for sterilization treatment. The scaffolds were 
rinsed in phosphate-buffered saline (PBS) multiple times 
and freeze-dried. The combinations of each scaffold are 
shown in Table 1.
Drug-release profile test
The release profile of DOX from the scaffold was determined 
by incubating a piece of scaffold in 1.0 mL of sterile PBS 
(pH = 7.4) at 37°C (n = 4) in a sterile incubator for differ-
ent time intervals. Scaffolds were placed in a 48-well plate 
(one scaffold/well) and the lid was closed tightly. At each 
time point, 1 mL of solution was collected and replaced with 
1 mL of fresh PBS. The fluorescence intensity of DOX in the 
buffer solution was quantified with a Victor 1420 multilabel 
counter (Wallac, Waltham, MA) with excitation at 405 nm 
and emission at 615 nm. The concentrations of DOX released 
in the solutions were calculated according to the calibration 
curve of DOX in PBS and the cumulative release rates were 
calculated afterwards.
Seeding hMSC-TERT cells  
to scaffold
A telomerase reverse transcriptase gene-transduced cell 
population, hMSC-TERT cells, was used in this study. These 
cells maintain the functional characteristics of primary MSCs 
and have the capability to differentiate into certain mesoder-
mal cell types (osteoblasts, chondrocytes, and adipocytes) 
in the presence of specific stimuli.32 Cells from population 
doubling (PD) level 262 (passage 45) were seeded at a density 
of 4000 cells/cm2 in culture flasks in Dulbecco’s Modified 
Essential Medium (DMEM; Invitrogen, Life Technologies, 
Carlsbad, CA) containing 10% fetal bovine serum (FBS; 
Invitrogen) and cultivated in a humidified atmosphere of 
37°C and 5% CO
2
. After one week, cells were washed 
in PBS, detached with 0.125% trypsin and 5 mM EDTA 
(Sigma-Aldrich) in PBS, reseeded, and cultured for another 
week. Cells were trypsinized (PD level 271, passage 47) and 
resuspended for use (2 × 107 cells/mL) in DMEM/10% FBS 
penicillin (100 U/mL; Sigma-Aldrich) and streptomycin 
(100 mg/L; Sigma-Aldrich).
PCL scaffold
(a) Tissue engineering test (b) Drug delivery test
Group C: PCL +
chitosan + β-TCP
+ clay/DOX
Group C: PCL +
chitosan + β-TCP
+ clay + DOX
Group B: PCL +
chitosan +
β-TCP + DOX
Group A: PCL +
chitosan +
β-TCP + clay
Figure 1 Schematic of composite scaffold preparation and groups.
Abbreviations: β-TCP, β-tricalcium phosphate; DOX, doxorubicin hydrochloride; 
PCL, polycaprolactone.
Table 1 Scaffold composition in different groups
Scaffold composition A B C D
1% chitosan (µL) 500 500 500 500
β-TCP (mg) 0.25 0.25 0.25 0.25
Clay (mg) 0.45 – 0.45 –
DOX (mg) – 0.1 0.1 –
Clay/DOX (mg) – – – 0.45/0.1
Abbreviations: β-TCP, β-tricalcium phosphate; DOX, doxorubicin hydrochloride.
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The hMSC-TERT cells were seeded onto the top of 
the scaffolds by pipetting 50 µL of cell suspension media 
with 1 × 106 cells onto each scaffold. The scaffolds were 
placed in agarose-coated (1% in sterile H
2
O) six-well 
plates (4 scaffolds/well), and incubated for 2 hours in an 
 incubator. Thereafter, additional 7.5 mL of DMEM/10% 
FBS, 100 U/mL penicillin, 100 mg/L streptomycin were 
added to each well. After 24 hours, cell/scaffold constructs 
were moved to 58 mm diameter dual side-arm spinner flasks 
(Bellco Glass, Vineland, NJ). An autoclavable stainless 
framework with four needles was constructed and placed in 
the spinner flasks. Two cell-seeded scaffolds were mounted 
on each needle giving a total of eight scaffolds per flask. 
Spinner flasks containing 120 mL of media were placed 
on a Bell-enniumTM five-position magnetic stirrer (Bellco 
Biotechnology, Vineland, NJ) at 30 revolutions per minute 
in the incubator with side arm caps loosely attached.
Cell/scaffold constructs were cultured with DMEM/10% 
FBS for the first week, and then the medium was replaced 
with osteogenic stimulation medium (DMEM/10% FBS with 
100 nM dexamethasone, 290 µM ascorbic acid and 5 mM 
β-glycerophosphate) (all from Sigma-Aldrich) and cultured 
for up to 21 days. Medium was exchanged twice a week.
Cellular adhesion, viability  
and proliferation of hMSC-TERT  
cellular scaffolds
Scanning electron microscope (SEM)
Scaffolds from day 1, day 7, day 14, and day 21 were rinsed 
in PBS and fixed in 2.5% glutaraldehyde containing 0.1 M 
sodium cacodylate buffer (pH 7.4) and dehydrated in a 
graded ethanol series, air-dried. The samples from day 21 
with cell culture and day 0 without cell culture were viewed 
using environmental mode SEM (Nova NanoSEM 600; FEI 
Company, Hillsboro, OR) and the element component of the 
crystal-like structure was analyzed by means of an energy 
dispersive X-ray spectrometer (EDX).
Confocal imaging
To assess cell viability, the cell/scaffold constructs were 
incubated for 30 minutes in DMEM containing 10 µM 
CellTrackerTM Green CMFDA (Invitrogen). The staining 
medium was then replaced with fresh DMEM/10% FBS and 
incubated for another 30 minutes at 37°C. Non-fluorescent 
CMFDA was converted to a bright green fluorescent product 
when cytosolic esterases cleaved off the acetates. The cell/
scaffold constructs were then rinsed in prewarmed PBS, fixed 
in 10% formalin for 5 minutes at room temperature, and 
stained with 1 µg/mL Hoechst 33258 (Sigma-Aldrich) in PBS 
for 20 minutes. Living cells were labeled with green pixels. 
Nuclei of the cells were stained with Hoechst, labeled with 
red pixels. Chitosan were stained with yellow pixels result-
ing from the spatial overlap of red and green pixels. Images 
were acquired using a laser scanning confocal microscope, 
510 Meta (Zeiss Microimaging GmbH, Jena, Germany). 
The confocal settings (excitation, laser power, detector 
gain, and pinhole size) were the same for all cell imaging. 
Separate channels and filters were used. Excitation/emission 
wavelengths were 488 nm/BP505-530 nm for CellTrackerTM 
Green and 405 nm/LP420 nm for Hoechst.
DNA quantification
The total cell number in the 3D cellular scaffold was esti-
mated by quantifying the dsDNA content in each scaffold 
using the Quant-iT™ PicoGreen® dsDNA assay (Invitro-
gen). Scaffolds were thawed and sonicated at intervals of 
1 second on/5 seconds off for a total of 1 minute. Three 
milligrams of collagenase (Sigma-Aldrich,) were added 
to each DNA sample and the samples were incubated in a 
37°C water bath for 3 hours. One mg proteinase K (Sigma-
Aldrich) was then added and the samples were incubated 
overnight in a 45°C water bath. Sample volume was diluted 
1:10 in a Tris–EDTA buffer and vortexed in order to release 
DNA from scaffold debris. From each sample, 2 × 50 µL 
were drawn, 50 µL of PicoGreen (diluted 1:200 in TE 
 buffer) was added, then the mixture was incubated in dark-
ness for 5 minutes and measured into a 96-well plate using 
a microplate reader, Victor3 1420 Multilabel Counter, 
 (PerkinElmer, Waltham, MA). Samples were excited at 
480 nm, and the fluorescence emission intensity was mea-
sured at 520 nm. Standards were prepared according to the 
manufacturer’s instructions (lambda DNA, concentration 
range: 0–1 µg/mL). Technical duplicates were used for each 
biological sample (n = 4).
Osteogenic differentiation  
and mineralization of hMSC-TERT  
cells in a 3D scaffold
Alkaline phosphatase (ALP) activity assay
ALP activity was determined using a colorimetric endpoint 
assay measuring the enzymatic conversion of p-nitrophenyl 
phosphate (Sigma-Aldrich) to the yellowish product, p-nitro-
phenol, in the presence of ALP. p-Nitrophenol absorbance 
was measured by means of a microspectrophotometer (Vic-
tor 1420; Perkin Elmer) at double wavelengths of 405 nm 
and 600 nm. Standards were prepared from p-nitrophenol 
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(concentration range: 0–0.2 mM). Technical duplicates were 
used for each  biological sample (n = 4).
von Kossa staining
The scaffolds were rinsed with PBS and fixed for 5 minutes 
in 4% (w/v) formaldehyde solution (pH 7.0), then washed 
with ddH
2
O, incubated in darkness with a 2.5% silver nitrate 
solution for 20 minutes, and subsequently developed by 
adding 0.5% hydroquinone for 2 minutes. Finally, surplus 
silver was removed using sodium thiosulphate for 5 minutes. 
The scaffolds were dried under vacuum and pictures were 
taken afterwards.
Calcium content assay
Calcium contents of cell-seeded scaffolds were quantified 
using a colorimetric endpoint assay based on the complex-
ation of one Ca2+ ion with two Arsenazo III molecules to 
a blue-purple product (Diagnostic Chemicals Limited, 
Charlottetown, PEI, Canada). The calcium deposition was 
dissolved in 1 M acetic acid by placing it in a shaker over-
night. The samples were diluted 1:50 with ddH
2
O and aliquots 
of 20 µL were transferred to a 96-well plate. Arsenazo III 
solution (280 µL) was added and incubated for 10 minutes 
at room temperature. A standard dilution series of calcium 
ranging from 0 to 50 µg/mL was prepared and Ca2+ concen-
tration was quantified spectrophotometrically at 650 nm. 
Calcium content was expressed as micrograms of Ca2+ per 
scaffold.
Histology and immunohistochemistry
The scaffolds were fixed in 70% ethanol, Technovit® 7100 
(Ax-lab, Vedbæk, Denmark) embedded, and cut into 25 µm 
sections using a Sawing Microtome KDG 95 (Mepro-
tech, Dirkshorn, the Netherlands). Sections were taken 
from the peripheral and the central part of the  scaffold. 
 Hematoxylin and eosin staining was applied in order to 
reveal cell  distribution. Histochemical staining for ALP 
was performed to test the osteogenic phenotype of cells 
cultured in the scaffolds. For immunohistochemistry, the 
sections were incubated overnight with rabbit anti-human 
osteocalcin antibody (BT593; Biomedical technologies 
Inc, Stoughton, MA), followed by biotinylated goat anti-
rabbit IgG (E0432; DAKO, Glostrup, Denmark) for 1 hour, 
and peroxidase-conjugated streptavidin (P0397; DAKO) 
for 1 hour. Sections were visualized with 3-amino-9-
 ethylcarbazol (A6926; Sigma-Aldrich) and counter-stained 
with Mayer’s  hematoxilin. With the same staining procedure, 
sections stained without the primary antibody of the rabbit 
anti-human osteocalcin served as control. Images were 
photographed using a BX50 microscope with a Camedia 
C-5060 camera  (Olympus, Tokyo, Japan).
Statistical analysis
Results are presented as mean ± standard deviation (SD) for 
n = 4 biological replicates. The data of DNA quantification, 
ALP activity, and calcium content were analyzed by one-way 
analysis of variance (ANOVA) using the Statgraphics  Centurion 
XVI software version 16.1.05 (Statpoint  Technologies, Inc, 
Warrenton, VA). Data were tested for normal distribution and 
variance homogeneity using Levene’s-test. Multiple range test 
(LSD 95%) was used to identify differences between sampling 
days at the 5% significance level.
Results
Drug release from scaffolds
DOX without modified clay, DOX with modified clay, and 
clay/DOX carrier were each incorporated into individual 
scaffolds. The release profile of DOX from these three 
different composite scaffolds is shown in Figure 2. There 
was an initial burst release in all the groups. On day 4, 
DOX released 94% of the total amount of drug from the 
Group B control scaffolds (prepared without modified 
clay). Whereas, the clay incorporated scaffolds released 
far less amounts of drug loaded: 13% from Group C 
scaffolds (prepared by direct mixing with modified clay 
and DOX) and 15% from Group D scaffolds (prepared 
with clay/DOX carrier). The cumulative drug release was 
significantly lower from Group C scaffolds than Group D 
scaffolds on day 5 (P = 0.04). By day 56, about 33% was 
released by Group C scaffolds and 47% was released by 
Group D scaffolds.
Cell adhesion, viability and proliferation  
in the scaffold
Scanning electron microscopy (Figure 3A) shows the 
cells and extracellular matrix deposition on the scaffolds. 
On day 1, the cells anchored tightly on the surface of the 
 scaffold. Cells were adhered and spread well on the scaffold. 
On day 7, cells and extracellular matrix deposition partially 
covered the scaffold. Increasing density and extracellular 
matrix deposition almost completely covered the scaffold 
on day 14. Crystal-like extracellular matrix deposition was 
observed on the surface of the scaffold of the 21 day  culture. 
These deposits were expected to be calcium phosphate and 
were further identified by element component analysis 
(energy dispersive X-ray spectrometer) to consist mainly of 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4289
A scaffold for bone tissue engineering and drug delivery
International Journal of Nanomedicine 2012:7
P, Ca, and O. Compared to the scaffold without cell culture 
on day 0, the amount of calcium increased significantly.
Confocal microscopy images (Figure 3B) showed good cell 
viability in the scaffolds during the 21 days of  culturing. Cells 
attached and spread in the scaffolds from day 1. Cells migrated 
into the macro- and micropores of the s caffolds and spread 
evenly on the surface of the scaffolds. Cell density increased 
steadily as the culturing period progressed. Higher magnifica-
tion showed that the cells grew into the chitosan structure and 
proliferated rapidly (the nuclear density increased).
The DNA amount was assumed to be proportional to 
the cell number. Thus, cell proliferation over time could 
be followed by quantification of the extracted DNA from 
the scaffolds. DNA amounts increased during the culturing 
period (Figure 3C).
Osteogenic differentiation  
and mineralization of hMSC-TERT  
cells in the 3D scaffold
ALP activity was highest on day 7, then decreased at day 
14, after which the same level was maintained until day 21. 
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Figure 2 Cumulative DOX release (%) from group B (DOX without clay scaffold), group C (DOX with clay scaffold), and group D (Clay/DOX carrier scaffold) at 37°C 
in PBS (pH 7.4) for 2 months.
Abbreviations: PCL, polycaprolactone; β-TCP, β-tricalcium phosphate; DOX, doxorubicin hydrochloride; PBS, phosphate-buffered saline.
This suggests that the cells started to initiate mineralization 
on day 7 (Figure 4A).
ALP positive staining (brown color) confirmed the 
presence of ALP, which was a component and marker for 
extracellular matrix produced by osteogenic differentiated 
cells (Figure 4B).
Quantitative data of calcium content (Figure 4C) and von 
Kossa staining (Figure 4D) showed that the scaffolds were 
osteoinductive.
Histology
Cross-sections of the scaffold with hematoxylin and eosin 
staining revealed the cellular distribution within the scaffold 
(Figure 5A). Nuclei were stained dark blue (basophilic), 
extracellular matrix and cytoplasm were stained purple, and 
the chitosan foam was stained orange. Cells migrated into the 
center of the scaffolds within 7 days of culture and the pores 
of the scaffolds were partly filled with cells and extracellular 
matrix. The depth of cell infiltration and the density of the 
cells increased as culturing progressed. On day 21, cells had 
fully filled the macro- and micropores of the scaffolds.
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Positive osteocalcin staining (red dots, pointed with 
arrows) showed that hMSCs-TERT cells had undergone 
osteogenic differentiation and secreted bone-related extracel-
lular matrix marker-osteocalcin (Figure 5B).
Discussion
We fabricated a drug-eluting scaffold consisting of two main 
parts: a rapid prototyped PCL scaffold for mechanical sup-
port and an embedded chitosan/nanoclay/β-TCP composite 
for sustained drug delivery and enhancement of osteogenesis. 
This composite scaffold had a favorable environment for 
cell attachment, proliferation, and osteogenic differentiation 
of hMSCs. This scaffold also had the capacity to load and 
release an anticancer drug in a sustained manner. The present 
study suggests that the composite scaffold has the potential 
to be a drug-eluting bone graft substitute.
In the clinic, tumor resection is followed by systemi-
cally administered chemotherapy to prevent tumor recur-
rence. The limitations of systemic drug administration are 
limited bioavailability at the tumor site, systemic toxicity, 
and other adverse effects. Although systemically adminis-
tered tumor-targeted drug delivery has been a great focus 
of advanced drug-delivery research, no breakthrough prod-
ucts for clinical use are as yet on the market. At present, 
local sustained drug release from an implanted device at 
the tumor site is a more realistic approach. The Gliadel® 
Wafer (Eisai Inc., Tokyo, Japan) is an early example of 
a sustained drug delivery device that can be implanted 
locally as an adjunct to surgery for malignant glioma. 
 Various local drug-delivery systems for different tumor 
types have been researched. Itokazu et al showed that 
methotrexate released from porous hydroxyapatite blocks 
and β-TCP blocks remained effective against tumor cells 
for up to 12 days in vitro.33 El-Ghannam et al tested a 
ceramic-based anticancer drug to treat breast cancer in a 
murine model.34 However, it was difficult to tune the drug 
amount and release kinetic in those systems.
Many studies have used clay to enhance the solubility 
of poorly soluble drugs and to promote sustained release. 
 Ofloxacin has been controllably released from chitosan/clay 
hydrogel beads.21 A pseudo-zero-order release kinetics of 
 vitamin B12 was observed from clay/chitosan  nanohydrogel.22 
Wang et al showed that BSA could be controllably released 
from clay nanoparticles.35 However, the ultimate goals of all 
these studies were to use clay or clay composite as a simple 
drug carrier rather than as a component in an implantable 
device. Therefore, we included the montmorillonite clay in 
the drug-eluting matrices in this study.
Figure 3 Cell adhesion, viability, and proliferation in the scaffolds. (A) SEM images 
of cellular scaffolds from the cell seeding side on Days 1, 7, 14, and 21. The arrows 
point to the cells on Day 1 and to the crystal-like extracellular matrix deposition 
on Day 21. EDX analysis of the element components revealed the mineralized 
nodules as calcium phosphate salts, consisting of P, Ca, and O elements in the cell 
culture scaffold for Day 21, compared to day 0 in the cell free scaffold. (B) Confocal 
micrographs of cell viability on Days 1, 7, 14, and 21. green pixels: live cells; red 
pixels: nuclei; green and red pixel overlap: chitosan structure. Upper panels show 
projections of a 150 µm optical section onto a single plane (magnification 5×). 
Bottom panels show single planes at magnification 20×. (C) Quantification of dsDNA 
in cellular scaffolds by means of Picogreen assay on Days 1, 7, 14, and 21. 
Notes: The amount of DNA is expressed as mean ± SD (n = 4). Different letters 
(a–c) indicate significant differences (P , 0.05) between sampling days.
Abbreviations: ALP, alkaline phosphatase; SEM, scanning electron microscopy; 
EDX, energy dispersive X-ray spectrometer.
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Figure 4 Osteogenic differentiation and mineralization of cellular scaffolds. (A) Activity of the ALP enzyme on Days 1, 7, 14, and 21. The activity is expressed as mean ± SD 
(n = 4). Activity is indicated in nanomole p-nitrophenol/microgram DNA per minute (nmol/µg DNA * min). Different letters (a–c) indicate significant differences (P , 0.05) 
between sampling days. (B) ALP staining. (C) Calcium contents per scaffold on Days 1, 7, 14, and 21. The amount of calcium is expressed as mean ± SD (n = 4). Different 
letters (a–c) indicate significant differences (P , 0.05) between sampling days. (D) von Kossa staining of scaffolds.
Abbreviations: ALP, alkaline phosphatase; SD, standard deviation.
We chose sodium montmorillonite due to its high cation 
exchange capacity, good absorbance, and drug carrying 
 capability. The structure of montmorillonite clay consists 
of one shared edge of an octahedral sheet of aluminum 
hydroxide fused in between two silica tetrahedrals.36 It has 
a plate-like layer with the thickness of 1 nm and a high 
aspect ratio (ratio of length to thickness), which gives it a 
large  surface area and makes it suitable for reinforcement 
purposes. These layers can stack and lead to a regular van 
der Waal’s gap between layers. In the interlayer region, there 
exist exchangeable cations such as Na+ and Ca2+, which enable 
intercalation with drugs and polymers.
The principle of our composite scaffold with drug-eluting 
matrix embedding is shown in Figure 6. The experiment ratio-
nale of the designed composite scaffold is two-fold: firstly, 
to show the successful loading and release of a chemothera-
peutic drug, doxorubicin, and secondly, to test the drug-free 
 composite for bone tissue repair using hMSC. All the tests 
were done in vitro as shown in Figure 1. The drug was released 
sustainably from the composite scaffolds for 2 months. About 
45% DOX was released after 56 days from the scaffold when 
clay was incorporated into a chitosan/β-TCP matrix. In con-
trast, about 95% DOX was released within 4 days from the 
scaffolds without clay. This confirms that clay is an effective 
material in drug delivery modulation.
Even with the same amount of modified clay in the scaf-
folds, a faster drug-release rate was observed when clay/DOX 
carriers were first prepared and mixed in the chitosan/β-TCP 
solution (Figure 2, Group D). A slower drug-release rate 
was observed when the drug was directly mixed with modi-
fied clay in the chitosan/β-TCP solution during the scaffold 
preparation (Figure 2, Group C). It is postulated that DOX 
intercalates into clay layers by replacing Na+. The pKa of 
DOX is around 8.3 and the drug loaded composites are pre-
pared in acidic pH. Under the acidic pH, the drug molecules 
will be positively charged. When DOX and clay were directly 
mixed with the chitosan/β-TCP solution, DOX (pKa ∼ 8.3) 
and chitosan (pKa ∼ 6.3) competitively replaced Na+ ions 
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Figure 5 Histology results. (A) Representative histology micrographs of H&E 
stain showing cross-sections of the top part of cell/scaffold constructs after 
7-day and 21-day culture. Bars = 1 mm. Nuclei are stained dark blue (basophilic), 
ECM and cytoplasm are stained purple, and the chitosan foam is stained orange. 
(B) Immunohistology staining of anti-human osteocalcin of the scaffolds after 21-day 
culture. Sections stained without anti-human osteocalcin served as control. 
Note: Arrows point to representative positive staining of osteocalcin.
Abbreviations: OC, osteocalcin; H&E, hematoxylin and eosin; ECM, extracellular 
matrix.
Figure 6 Principle of the composite scaffold with drug eluting matrix embedding. 
(A) Following tumor resection, remnant tumor cells (orange) may be present and 
there is an increased risk of recurrence. (B) Implantation of mechanically stable 
porous scaffold with controlled drug release functions will provide immediate load 
bearing support and localized anti-cancer treatment. (C) After all the drug has been 
released, the implant will aid in tissue regeneration of the wound site.
in the clay layers. The smaller and more positively charged 
DOX could replace more Na+ ions than chitosan. As a result, 
the binding affinity with clay and DOX was stronger and 
release was slower in Group C scaffolds. Yuan et al also 
showed that DOX release from clay was much slower than 
from a chitosan/clay composite carrier.23 When the drug 
was loaded to a chitosan/clay nanocomposite prior to the 
composite preparation as in Group D scaffolds, no competi-
tive intercalation and exfoliation of the clay was expected. 
Therefore, the drug-release rate was faster as a low affinity 
of DOX to clay was anticipated.
Therefore, tunable drug-release rates from the scaffold can 
be created by adjusting the amounts and types of chitosan in 
chitosan-clay composite preparations. The ratios between clay 
and chitosan of the composites could accomplish the same 
result. A study by Hua et al showed that increasing the ratio of 
clay to chitosan enhanced drug entrapment and reduced drug 
release.21 Similar effects were observed in biopolymer/clay 
nanocomposites.35 These studies indicated that drug-release 
kinetics could be adjusted by altering clay/chitosan/drug ratios 
and compositions in our composite scaffolds.
For biomedical applications, Katti et al reported that a 
novel chitosan/clay/hydroxyapatite sheet is biocompatible 
and, in comparison to pure chitosan as well as chitosan/
hydroxyapaptite and chitosan/clay, possesses improved 
mechanical properties.24 In another study, they showed that 
chitosan/polygalacturonic acid scaffolds containing modi-
fied montmorillonite clay appeared to satisfy some of the 
basic requirements of scaffolds for bone tissue engineering 
 applications.25 Chitosan/clay nanocomposites are also poten-
tial sustained drug-release carriers.21–23
The second objective of the study was to test if the drug-
free composite scaffold (or drug-depleted scaffold in a clini-
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cal setting) is suitable for bone repair, because patients need 
bone grafts or artificial bone implants to be replaced at the 
resected tissue in order to provide immediate mechanical sup-
port and bone regeneration. In this study, we chose the rapid 
prototyped PCL scaffold to house the chitosan/clay/ β-TCP 
composite because the rapid prototyped scaffolds can be 
fabricated to resemble the shape and mechanical strength of 
bone.37 The intertwined network of the chitosan/nanoclay/β-
TCP composite was designed to provide better biocompat-
ibility and osteogenesis. Calcium phosphates like β-TCP 
and hydroxyapatite were widely applied as coatings on other 
implants like titanium to achieve faster and greater bone 
ingrowth.38,39 Chitosan has also been widely investigated 
for bone tissue engineering and drug delivery because of its 
favorable biological properties including biocompatibility, 
biodegradability, nontoxicity, osteoconductivity, and anti-
bacterial properties.40 However, both β-TCP and chitosan 
have lacked the necessary mechanical properties to mimic 
bone because β-TCP is brittle and porous chitosan scaffolds 
showed inferior tensile and compressive strength in compari-
son to natural bone.41–43 Clay is a silicate compound, a class 
of ceramics that is gaining increasing interest in biomedical 
applications.44–46 Katti et al showed that a nanocomposite 
sheet of chitosan/clay/hydroxyapatite was biocompatible and 
had significantly improved nanomechanical properties.24
We cultured hMSCs-TERT cells in our scaffolds and 
observed high cell viability and cell infiltration, confirmed 
by SEM, confocal microscopy, and histology. In particular, 
a very highly increased Ca2+ deposition rate was observed 
compared to our f irst study with hyaluronic acid and 
methylated collagen.47 The Na → Ca exchange equilibrium 
constant for sodium montmorillonite is close to 1,48 so when 
found in cell culture media or blood plasma, which contains 
approximately 60 times more sodium than calcium, the 
majority of metal cations in the clay would be Na+. Chitin, 
chitosan, and their derivatives readily bind to divalent cat-
ions, with particular affinity for heavy metal ions but still 
including Ca2+.49–51 This chelation property has been studied 
extensively for use in wastewater treatment. Rats fed with 
chitosan-enriched diets have decreased mineral absorption 
with a resulting decrease in bone quality.52 Consequently, 
we performed a control experiment with cell-free scaffolds 
in similar cell culture media and measured Ca2+ deposition 
for 21 days (Figure 7).
Our suspicions were confirmed, as the cell-free scaffolds 
had a similar amount of calcium deposition comparable to 
the cell-seeded scaffolds up to day 7 and had nearly two 
times the amount of calcium at day 14 and three times at 
day 21 compared to the cell-seeded scaffolds. The increas-
ing progression of the graph can be explained by the regular 
media change with corresponding replenishment and further 
binding of Ca2+ in the scaffold. Dynamic culture and the 
large surface area of the chitosan foam have most likely been 
major contributors to the thorough accumulation of calcium. 
As seen in Figure 5A, the slowed calcium deposition in the 
cell-seeded scaffolds coincides with the increasing cellular-
ity, which decreases the exposed surface area of the chitosan 
foam inside the scaffold and decreases metabolite and ion 
exchange rate by obliterating the scaffold pores.
Numerous papers in bone tissue engineering have stud-
ied the biocompatibility of chitosan scaffolds in vitro and 
used calcium assays and von Kossa staining to conclude the 
osteoinductive capability of the material.53–56 The majority of 
these studies do not show mineralization data from cell-free 
controls. As seen in this study, although chitosan is clearly 
highly biocompatible and osteoconductive,40,57,58 the osteoin-
ductive potential of this particular ionotropic biomaterial 
should not be evaluated only by the calcium deposition. We 
included an immunostaining against osteocalcin (Figure 5B) 
to qualitatively demonstrate osteogenic differentiation in the 
scaffold.
With the same amount of seeding cells, the measured 
DNA content is lower than that of the scaffold in the first 
study using hyaluronic acid and methylated collagen.47 This 
could be due to inefficient extraction of DNA in the presence 
of a cationic polymer like chitosan. Chitosan readily forms 
complex coacervates with free DNA, which makes it useful 
for making DNA-chitosan nanoparticles for drug delivery.59 
It is unlikely that the clay contributed to DNA retention, as its 
absorption of polycations at physiological pH is minimal.60 
Day 1 Day 7 Day 14 Day 21
0
500
1000
µg
 c
al
ci
u
m
/s
ca
ff
o
ld
1500
2000
2500
Cell_seeding scaffold
Calcium quantification assay
Cell_free scaffold
Figure 7 Calcium deposition contents per scaffold on cell-free scaffolds in 
comparison with cell-seeded scaffolds on Days 1, 7, 14, and 21.
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Therefore, Picogreen used for DNA quantification cannot 
intercalate a DNA-chitosan complex and an underestimated 
value is to be expected.
ALP quantification measures the activity, ie, the amount 
of a protein macromolecule in the purified supernatant, and 
should not be affected by the adsorption and chelation prop-
erties of clay and chitosan.
Therefore, the optimal combination of four biomaterials 
(PCL, chitosan, β-TCP, and clay) will potentially prove to 
be a much needed contribution in terms of filling a vital gap 
in the field of therapeutic implant. Further in vivo studies on 
this composite scaffold are underway as the more realistic 
conditions for bone repair occurred after the release of che-
motherapeutic drugs.
Although it is mere speculation at this juncture, further 
development of the therapeutic implant can be envisioned 
from this work. The concept of using rapid prototyped 
PCL as a biocompatible structural support, and soft clay 
composites as a drug reservoir, can be extended for the 
treatment of different tissues that require local sustained 
drug release. The only limitation will be the choice of 
polymer for effective dispersion of clay. The composite 
has to be reproducible for both sustained drug delivery 
and tissue repair. Other naturally derived polymers, such 
as alginate and gelatin, will also be good candidates for 
preparation of the composite. Instead of a cation exchanger 
like sodium montmorillonite, an anion exchanger can also 
be applied in this system for carrying different properties 
of drugs. In this case, a different class of clays, layered 
double hydroxides, would be used. Since the amount and 
type of drug needed for different patients vary from subject 
to subject and the severity of the medical implications, 
personalized therapeutic implants are necessary.  Designing 
a composite scaffold based on the concept of this work 
will further contribute to the development of personalized 
medical care.
Conclusion
We fabricated a 3D hybrid scaffold composed of two main 
parts: a rapid prototyped PCL scaffold for mechanical sup-
port and chitosan/clay/β-TCP for enhanced bone repair and 
local sustained drug delivery. The composite scaffold design 
offered a favorable environment for cell attachment, prolif-
eration, and osteogenic differentiation of hMSC-TERT. The 
developed scaffold could provide a sustained drug release 
of the loaded doxorubicin. Doxorubicin was used in this 
study as a model drug to demonstrate the release kinetic 
of the drug from the scaffold. The tunable characteristic of 
clay composite to carry drug was also explained based on 
the extent of intercalation in clay. By applying the concept 
of this scaffold design, local sustained drug-release tissue 
engineering scaffolds can be developed for the treatment of 
diseases in other tissues.
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